Speaker Profile
Ph.D., VP, Scribe Tx
Biography
Brett Staahl, Ph.D., is Co-Founder and Vice President of External Innovation at Scribe Therapeutics, where he works on next-generation CRISPR technologies and their translation into genetic medicines. During his postdoctoral training in Jennifer Doudna’s laboratory at the University of California, Berkeley, he helped pioneer delivery of preassembled CRISPR-Cas ribonucleoprotein complexes for genome editing in vivo and ex vivo. His research has included approaches to gene inactivation in disease models, including applications relevant to the nervous system and neurodegeneration. Earlier, Dr. Staahl earned his Ph.D. in developmental biology at Stanford University, studying genetic circuitry in the nervous system and mechanisms relevant to amyotrophic lateral sclerosis. At Scribe, he has helped advance compact, highly active CRISPR systems designed for therapeutic use and scalable delivery. His work sits at the intersection of genome-editing biology, delivery, and drug development, with a focus on turning programmable molecular tools into medicines that can address genetically defined disease.
Session Abstract – PMWC 2027 Silicon Valley
Track Chair:
Cindy Perettie, Kite Pharma
PMWC Award Ceremony
• Katy Rezvani, MD Anderson (Luminary)
• David Miklos, Stanford (Luminary)
• Frederick Locke, Moffitt Cancer Center (Luminary)
Featured Speakers
• Katy Rezvani, MD Anderson
• David Miklos, Stanford
• Frederick Locke, Moffitt Cancer Center
• Arie Belldegrun, Allogene Therapeutics
• Paul Hastings, Nkarta Therapeutics
• Priti Hegde, Kite Pharma
• Andrew Scharenberg, Umoja Biopharma
• Brett Staahl, Scribe Therapeutics
• Marcela Maus, Mass General Brigham / Harvard
• Antoni Ribas, UCLA
• Saul Priceman, USC
• Sabine Heitzeneder, Stanford
Off-the-Shelf Cell Therapies
NK, iPSC, and allogeneic T cells: what wins beyond autologous CAR-T.
AI in Cell Therapy: Research to Commercialization
How AI is reshaping discovery, product design, manufacturing, and clinical translation.
The Bottleneck: Manufacturing at Scale
Capacity, automation, cost of goods, and the realities of getting engineered cells to patients.
In Vivo Delivery: The Make-or-Break Layer
Targeting the right tissue safely enough to make in vivo engineering real.
Why Cell Therapies Fail in Solid Tumors and What Works
The microenvironment, antigen escape, and programs showing real responses.
Approved to Effective
Real-world outcomes, access, and what CAR-T still gets wrong after approval.
Davos of Precision Medicine
PMWC 2027 Program
January 27–29, 2027 · Santa Clara Convention Center
Swipe speakers · Tap a card for sessions →
In a few words.
PMWC is indeed The Davos of Biotech
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
